Testing tarlatamab with temozolomide for teens and adults with brain and spinal cord tumors
Original title: Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to check safety and first signs of whether it helps.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests whether two drugs used together are safe and whether they help against certain brain tumors.
Who this trial is for. This trial is for teens and adults with tumors of the brain or spinal cord, including gliomas. First, a sample of a person's past tumor is tested for a marker called DLL3, and only people whose tumor has it can get the drugs.
Where it stands. The trial is checking how safe tarlatamab is when given with a set dose of temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary. It is also looking at whether the drugs act on the tumors. The trial has not reported results yet.
What this means, and what it doesn't
What it could mean: This is one way researchers are trying to learn more about treating these tumors. If you or someone you care for might fit, you could ask your care team about it. The trial team decides who can join.
What it doesn't mean: A trial is a test, not a proven treatment. Taking part does not promise that it will help. This is not a cure, and it is not a sign that one has been found.
Source: ClinicalTrials.gov, September 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.